LANSING, Mich. (Michigan News Source) – What started as a medical treatment has quickly morphed into a cultural movement.
GLP-1 drugs – short for glucagon-like peptide-1 – were originally designed to help people with diabetes manage blood sugar. Now, they’ve exploded into one of the hottest weight-loss trends in the country. Medications like Wegovy, Ozempic, Zepbound, and Mounjaro mimic a natural hormone that slows digestion and signals fullness, helping users eat less and shed pounds.
MORE NEWS: Pressure Mounts on Michigan Secretary of State Jocelyn Benson Over Ties to Indicted SPLC
Celebrities are using them, telehealth companies are pushing them, and everyday Americans are lining up for prescriptions. Even Weight Watchers – long known for preaching portion control and lifestyle changes – is now offering access to GLP-1 drugs, marking a major shift in how weight loss is marketed and managed.
From meal plans to monthly prescriptions.
The rise of GLP-1 drugs is definitely changing the weight-loss playbook. Instead of tracking calories, measuring portions, and committing to long-term habit changes, many people are turning to weekly injections or daily pills that promise results with far less effort. It’s a shift from discipline to dependency – where the focus moves from learning how to eat differently to relying on medication to do the heavy lifting. And for many users, this isn’t a short-term fix. These drugs are often designed to be taken long-term to maintain results. That turns what looks like a quick solution into an ongoing commitment – both medically and financially.
According to a report in the Journal of the American Medical Association (JAMA), almost one in eight adults in the United States admitted to having tried a GLP-1 medication, about 40% of them saying they were being used for weight loss. And although most said they got their prescriptions from a physician or specialist, about 20% got them from other sources including weight-loss clinics, medical spas or online providers. And because many health insurance plans don’t pay for their prescription, 24-27% of adults are paying out of pocket according to a KFF Health Tracking Poll.
Side effects and unknowns.
While the weight loss may be real, the side effects are, too. According to FDA prescribing information for Wegovy – one of the earliest GLP-1 drugs to hit the market – common reactions include nausea, diarrhea, vomiting, constipation, and abdominal pain, with some affecting a notable share of users.
More serious risks are also listed, including pancreatitis, gallbladder disease, kidney problems, increased heart rate, and even warnings about possible suicidal thoughts. There’s also a warning in the data tied to thyroid tumors seen in animal studies, though the long-term risk in humans remains unclear.
Clinical trials have shown the drugs can be effective for weight loss, but most studies have followed patients for a limited period – often around a year to a year and a half. Widespread, long-term use on a massive scale is still playing out in real time, leaving some unanswered questions about what years – or decades – of use might look like.
Follow the money.
MORE NEWS: John James PAC Accused of Funding Opposition Tracking of Fellow Republicans
Behind the surge is a powerful financial engine. Drugmakers like Novo Nordisk (makers of Wegovy and Ozempic) and Eli Lilly (makers of Zepbound and Mounjaro) are raking in tens of billions from GLP-1 drugs, turning them into one of the most lucrative sectors in modern pharmaceuticals.
And with many health insurance plans not covering weight-loss drugs, patients are often paying out of pocket – sometimes hundreds to over $1,000 per month. That price tag has fueled demand for compounded versions, which are typically cheaper but come with added risks.
Compounded shortcuts, bigger risks.
Compounded GLP-1 drugs have become a booming alternative, largely because they promise lower costs and easier access. Some clinics and pharmacies offer “compounded” GLP-1 drugs. These still legally require a prescription, but oversight can be looser, and the process may be less strict. Telehealth platforms have made things simple: fill out an online form, get a prescription, and have the medication shipped to your door – often with minimal screening.
But unlike FDA-approved medications, compounded drugs aren’t held to the same standards for safety, effectiveness, or quality. They may use ingredients from unregulated sources, and in some cases, the mixing process itself can introduce risks. Experts warn that patients may be trading proven treatments for unverified alternatives – without fully understanding the potential consequences.
Psychology Today reports that these compounded drugs have significant safety issues “Because of less stringent regulatory oversight, patient safety may be compromised by contamination, inaccurate potency, or inconsistent quality.”
A Washington Post op-ed by Jimmie Wilson, president of the JADA Foundation, a nonprofit organization dedicated to supporting transplant patients and families, describes going into acute liver failure after taking a compounded drug that was prescribed by her doctor. Instead of an FDA- approved medication, she received a custom-mixed injectable from a compounding pharmacy that combined the drug with other ingredients. After taking it, she developed acute liver failure – her liver enzymes spiked, her condition rapidly deteriorated, and she ultimately required an emergency liver transplant to survive. The experience highlights the potential dangers of unregulated, copycat weight- loss drugs, especially those sourced or mixed without proper oversight or safety testing.
Cracking down on costly weight-loss shots in Michigan.
Cases like this are fueling broader concerns – not just about safety, but about cost and access – as policymakers begin taking a closer look at the booming weight-loss drug market. Michigan has already tightened the reins on popular GLP-1 weight-loss drugs for Medicaid patients, limiting coverage mainly to those classified as morbidly obese and only after other weight-loss methods have failed. The change, implemented at the beginning of this year, is part of a bipartisan state budget aimed at controlling costs after use of these drugs surged to more than 90,000 Medicaid patients. The state is expecting to save about $240 million because of the tighter eligibility restrictions and reduced coverage for weight-loss use of GLP-1 drugs
While medications like Ozempic and Wegovy will still be covered for diabetes, access for weight loss alone is now significantly restricted, marking a major shift in how Michigan handles the booming – and expensive – GLP-1 trend.
But while the state tightens the purse strings, it hasn’t tightened the rules. Michigan has yet to pass major legislation specifically targeting compounded GLP-1 drugs or telehealth prescribing practices, leaving a rapidly expanding corner of the market largely unchecked in the state.
The bottom line: easy weight loss, complicated trade-offs.
There’s no question GLP-1 drugs work – at least in the short term. The pounds come off, and for many, that’s enough. But the bigger picture is more complicated. What starts as a quick fix can turn into a long-term dependency, complete with ongoing costs, side effects, and unanswered safety questions.
